CITIUS PHARMAC. DL -,001

Citius Pharmaceuticals raised about $6 million through a registered direct placement, selling 3,973,510 common shares (or pre-funded warrants) at $1.51 per share. Accompanying warrants entitle holders to purchase an additional 3,973,510 shares at an exercise price of $1.40 and are exercisable immediately; term five years. H.C. Wainwright & Co. acted as exclusive placement agent; the offering was made under a shelf registration. The proceeds are intended primarily to fund the commercial launch of LYMPHIR, milestone and regulatory payments, continued development of other candidates and general corporate purposes. In parallel, subsidiary Citius Oncology closed a separate $9 million financing and expanded distribution agreements for LYMPHIR. » More on de.investing.com

Citius Oncology issued warrants to a financial advisor allowing the purchase of up to 360,000 common shares at an exercise price of $2.1875 per share (exercisable from March 10, 2026; expiring March 10, 2031). The board of directors increased the shares reserved under the 2024 Omnibus Stock Incentive Plan from 15,000,000 to 30,000,000. The company also reported recent financings (a public placement and a registered direct offering of roughly $9 million each), the filing of a prospectus supplement to update its S-1, and a distribution agreement with Cencora for the approved immunotherapy LYMPHIR. » More on de.investing.com

Citius Oncology raised about $9 million through a registered direct offering and a private placement by selling 5,142,858 common shares plus accompanying warrants at an effective price of $1.75 per share. The warrants are exercisable in six months (exercise price $1.84) and expire after five and a half years. In addition, the company completed another public offering of approximately $9 million and expanded distribution of LYMPHIR through an agreement with Cencora; no use of proceeds was disclosed. LYMPHIR received FDA approval in August 2024; however, the company has a low liquidity ratio (current ratio 0.35) and ongoing operating losses, so the financing is intended to strengthen the balance sheet. » More on de.investing.com